While Oncotype DX is a powerful tool, it has its limitations. It is not suitable for all types of breast cancer, such as HER2-positive or triple-negative breast cancers. Additionally, the test may not be as informative for patients with advanced or metastatic disease. It is essential to consider the test results in conjunction with other clinical factors and patient preferences.
